Price T Rowe Associates Inc Dyne Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,132,092 shares of DYN stock, worth $40 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,132,092
Previous 13,502
8284.62%
Holding current value
$40 Million
Previous $180,000
17756.11%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Atlas Venture Life Science Advisors, LLC8.02MShares$283 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$277 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$190 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$161 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$150 Million0.02% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.83B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...